Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Drug Metabolism And Disposition

• Publication date

  2011-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.111.039248PMID 21632965
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.

  2010cited by this paper
• Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans

  2010cited by this paper
• Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

  2010cited by this paper
• Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation.

  2010cited by this paper
• Population-Based Mechanistic Prediction of Oral Drug Absorption

  2009cited by this paper
• Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations.

  2008cited by this paper
• Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions

  2008cited by this paper
• Impact of pH on plasma protein binding in equilibrium dialysis.

  2008cited by this paper
• Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations

  2008cited by this paper
• Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds

  2008cited by this paper
• Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

  2008cited by this paper
• Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance

  2007cited by this paper
• Lack of Pharmacokinetic Interaction Between Anidulafungin and Tacrolimus

  2007cited by this paper
• Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam

  2007cited by this paper
• Solubility of sparingly-soluble ionizable drugs.

  2007cited by this paper
• Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects

  2007cited by this paper
• Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

  2007cited by this paper
• Prediction of intestinal first-pass drug metabolism.

  2007cited by this paper
• Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers.

  2007cited by this paper
• Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450‐3A Activity: Comparison With Grapefruit Juice

  2007cited by this paper
• Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects*

  2007cited by this paper
• Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

  2007cited by this paper
• Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine.

  2007cited by this paper
• Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition.

  2006cited by this paper
• Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

  2006cited by this paper
• Study of the Pharmacokinetic Interaction Between Simvastatin and Prescription Omega‐3‐Acid Ethyl Esters

  2006cited by this paper
• Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam

  2006cited by this paper
• Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism

  2006cited by this paper
• Pharmacokinetics of a Newly Identified Active Metabolite of Buspirone After Administration of Buspirone Over Its Therapeutic Dose Range

  2006cited by this paper
• THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

  2006cited by this paper
• Comparison of midazolam and simvastatin as cytochrome P450 3A probes

  2006cited by this paper
• Concomitant Tacrolimus and Micafungin Pharmacokinetics in Healthy Volunteers

  2005cited by this paper
• Studies to Investigate the Pharmacokinetic Interactions Between Ranolazine and Ketoconazole, Diltiazem, or Simvastatin During Combined Administration in Healthy Subjects

  2005cited by this paper
• Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

  2005cited by this paper
• Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin.

  2005cited by this paper
• Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

  2005cited by this paper
• The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids

  2005cited by this paper
• CYTOCHROME P450 3A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES

  2005cited by this paper
• Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.

  2005cited by this paper
• Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses

  2004cited by this paper
• Intravenous and oral alfentanil as in vivo probes for hepatic and first‐pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis

  2004cited by this paper
• Miniature Device for Aqueous and Non-aqueous Solubility Measurements During Drug Discovery

  2004cited by this paper
• Nisoldipine: Kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration

  2004cited by this paper
• Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans

  2004cited by this paper
• Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations

  2004cited by this paper
• Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.

  2004cited by this paper
• Pharmacokinetics of nisoldipine in renal dysfunction

  2004cited by this paper
• Influence of a Fat-Rich Meal on the Pharmacokinetics of a New Oral Formulation of Cyclosporine in a Crossover Comparison with the Market Formulation

  2004cited by this paper
• Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese.

  2004cited by this paper
• Effects of St. John's Wort (Hypericum perforatum) on Tacrolimus Pharmacokinetics in Healthy Volunteers

  2004cited by this paper
• Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens

  2004cited by this paper
• Development of a Whole Body Physiologically Based Model to Characterise the Pharmacokinetics of Benzodiazepines. 1: Estimation of Rat Tissue-Plasma Partition Ratios

  2004cited by this paper
• Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin.

  2004cited by this paper
• Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid

  2004cited by this paper
• Relation between retention factors of immunosuppressive drugs in microemulsion electrokinetic chromatography with biosurfactants and octanol-water partition coefficients.

  2003cited by this paper
• Whole Body Pharmacokinetic Models

  2003cited by this paper
• Human Jejunal Permeability of Cyclosporin A: Influence of Surfactants on P-Glycoprotein Efflux in Caco-2 Cells

  2003cited by this paper
• Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine.

  2003cited by this paper
• Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption.

  2003cited by this paper
• Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and Simvastatin

  2003cited by this paper
• Clinical Pharmacokinetics of Atorvastatin

  2003cited by this paper
• An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity

  2003cited by this paper
• Influence of Goldenseal Root on the Pharmacokinetics of Indinavir

  2003cited by this paper
• P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine

  2003cited by this paper
• Basic anatomical and physiological data for use in radiological protection: reference values

  2002cited by this paper
• Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

  2002cited by this paper
• The effects of portal shunts on intestinal cytochrome P450 3A activity

  2002cited by this paper
• Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.

  2002cited by this paper
• Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas.

  2002cited by this paper
• Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach.

  2002cited by this paper
• Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

  2001cited by this paper
• Effect of Grapefruit Juice on Pharmacokinetics of Microemulsion Cyclosporine in African American Subjects Compared with Caucasian Subjects: Does Ethnic Difference Matter?

  2001cited by this paper
• Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7.

  2001cited by this paper
• pH-metric solubility. 3. Dissolution titration template method for solubility determination.

  2001cited by this paper
• Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin

  2001cited by this paper
• A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.

  2001cited by this paper
• Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin

  2001cited by this paper
• Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.

  2001cited by this paper
• Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients

  2001cited by this paper
• Validation of methods to study the distribution and protein binding of tacrolimus in human blood.

  2001cited by this paper
• Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

  2000cited by this paper
• Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.

  2000influential reference
• Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.

  2000cited by this paper
• The interaction of diltiazem with simvastatin

  2000cited by this paper
• Plasma concentrations of active simvastatin acid are increased by gemfibrozil

  2000cited by this paper
• Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin

  2000cited by this paper
• Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations

  2000cited by this paper
• Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

  1999cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine

  1999cited by this paper
• A compartmental absorption and transit model for estimating oral drug absorption.

  1999cited by this paper
• Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

  1999cited by this paper
• 6′,7′‐Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P‐glycoprotein

  1999cited by this paper
• Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam

  1999cited by this paper
• Characterization of human small intestinal cytochromes P-450.

  1999cited by this paper
• Cyclosporine plasma unbound fraction in heart and lung transplantation recipients.

  1999cited by this paper
• Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers

  1999cited by this paper
• The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects.

  1999cited by this paper
• Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis.

  1999cited by this paper
• Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.

  1999cited by this paper

• Quantitative Analysis of the Effect of Gastrointestinal Water Dynamics on Oral Drug Absorption using a Physiologically Based Integrated Liquid and Intestinal Absorption Drug (ILIAD) Pharmacokinetic Model.

  2026cites this paper
• Quantitative analysis of the effect of controlled-release formulation on nonlinear gastrointestinal absorption of CYP3A4 substrate simvastatin using a physiologically based pharmacokinetic absorption model

  2026cites this paper
• Predicting Pharmacokinetics of Drugs in Patients with Heart Failure and Optimizing Their Dosing Strategies Using a Physiologically Based Pharmacokinetic Model

  2025cites this paper
• Integrating In Vitro Dissolution and Physiologically Based Pharmacokinetic Modeling for Generic Drug Development: Evaluation of Amorphous Solid Dispersion Formulations for Tacrolimus

  2025cites this paper
• Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro

  2025cites this paper
• Optimization of In Vitro CYP3A4 TDI Assay Conditions and Use of Derived Parameters for Clinical DDI Risk Assessment Using Static and Dynamic Models

  2025influential citation
• A Novel Colon PBPK Model: Navigating the Rational Drug Design for Small-Molecule Colon-Selective Therapies.

  2025cites this paper
• Quantitative in vitro to in vivo extrapolation for human toxicology and drug development

  2024cites this paper
• Predicting Food–Drug Interactions between Piperine and CYP3A4 Substrate Drugs Using PBPK Modeling

  2024cites this paper
• Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects

  2024cites this paper
• Guidance on Selecting Optimal Steady-State Tacrolimus Concentrations for Continuous IV Perfusion: Insights from Physiologically Based Pharmacokinetic Modeling

  2024cites this paper
• Quantitatively Predicting Effects of Exercise on Pharmacokinetics of Drugs Using a Physiologically Based Pharmacokinetic Model

  2024cites this paper
• Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease

  2023cites this paper
• A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients

  2023cites this paper
• Individual Dose Recommendations for Drug Interaction Between Tacrolimus and Voriconazole in Adult Liver Transplant Recipients: A Semiphysiologically Based Population Pharmacokinetic Modeling Approach.

  2023cites this paper
• A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19.

  2023cites this paper
• Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug

  2023cites this paper
• Investigating Tacrolimus Disposition in Paediatric Patients with a Physiologically Based Pharmacokinetic Model Incorporating CYP3A4 Ontogeny, Mechanistic Absorption and Red Blood Cell Binding

  2023cites this paper
• Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

  2023cites this paper
• Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.

  2023cites this paper
• Separate Evaluation of Fraction Absorbed and Intestinal Availability after Oral Administration of Drugs Based on the Measurement of Portal and Systemic Plasma Concentrations and Luminal Concentration.

  2023cites this paper
• Interaction of buspirone and its major metabolites with human organic cation transporters

  2023cites this paper
• In Silico Prediction of Human Clinical Pharmacokinetics with ANDROMEDA by Prosilico: Predictions for an Established Benchmarking Data Set, a Modern Small Drug Data Set, and a Comparison with Laboratory Methods

  2022cites this paper
• Predictive performance of next generation human physiologically based kinetic (PBK) model predictions based on in vitro and in silico input data_suppl1

  2022cites this paper
• Predictive Performance of Next Generation Human Physiologically Based Kinetic (PBK) Models Based on In Vitro and In Silico Input Data

  2022cites this paper
• Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib.

  2022cites this paper
• Impact of route-dependent phase-II gut metabolism and enterohepatic circulation on the bioavailability and systemic disposition of resveratrol in rats and humans: A comprehensive whole body physiologically-based pharmacokinetic modeling.

  2022cites this paper
• Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo

  2022cites this paper
• A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling

  2022cites this paper
• Drug-drug interactions

  2022cites this paper
• Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.

  2021cites this paper
• Guidance document on the characterisation, validation and reporting of Physiologically Based Kinetic (PBK) models for regulatory purposes

  2021cites this paper
• Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins

  2021cites this paper
• Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.

  2021cites this paper
• Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring

  2021cites this paper
• Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients.

  2021cites this paper
• GUIDANCE DOCUMENT ON THE CHARACTERISATION, VALIDATION AND REPORTING OF PBK MODELS FOR REGULATORY PURPOSES

  2021cites this paper
• Advances in Predictions of Oral Bioavailability of Candidate Drugs in Man with New Machine Learning Methodology

  2021cites this paper
• Prediction of Hepatic Drug Clearance with a Human Microfluidic Four-Cell Liver Acinus MicroPhysiology System.

  2021cites this paper
• Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models

  2020cites this paper
• The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug–Drug Interactions

  2020cites this paper
• IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.

  2020cites this paper
• Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery

  2020cites this paper
• Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes

  2020cites this paper
• Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method

  2020cites this paper
• Impact of Hepatic CYP3A4 Ontogeny Functions on Drug–Drug Interaction Risk in Pediatric Physiologically‐Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study

  2020cites this paper
• Impact of hepatic CYP3A4 ontogeny functions on DDI risk in paediatric PBPK/PD modelling: critical literature review and ivabradine case study

  2020cites this paper
• Predicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate

  2020cites this paper
• Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.

  2019cites this paper
• The nested enzyme‐within‐enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall

  2019cites this paper
• A Theoretical Physiologically‐Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition

  2019cites this paper
• A Minimal Physiologically‐Based Pharmacokinetic Model for Tacrolimus in Living‐Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype

  2019cites this paper
• Successful prediction of human pharmacokinetics after oral administration by optimized physiologically-based pharmacokinetics approach and permeation assay using human induced pluripotent stem cell-derived intestinal epithelial cells.

  2019cites this paper
• Human Efflux Transporters in Drug Disposition : in vitro Transport of Glucuronide Metabolites

  2019cites this paper
• Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I–IV drugs

  2018cites this paper
• Physiologically Relevant, Humanized Intestinal Systems to Study Metabolism and Transport of Small Molecule Therapeutics

  2018cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of the Bisphenols BPA, BPS, BPF, and BPAF with New Experimental Metabolic Parameters: Comparing the Pharmacokinetic Behavior of BPA with Its Substitutes

  2018cites this paper
• An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: the role of PBPK modeling

  2018influential citation
• In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems

  2018cites this paper
• Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.

  2017cites this paper
• Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models

  2017cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)

  2017cites this paper
• Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions

  2017cites this paper
• Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

  2017cites this paper
• A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions

  2017cites this paper
• A comparative evaluation of models to predict human intestinal metabolism from nonclinical data

  2017cites this paper
• Quantifying gut wall metabolism: methodology matters

  2017cites this paper
• Physicochemical and Biopharmaceutical Factors Affecting Hepatic/Intestinal First-Pass Effect

  2017cites this paper
• Bio-relevant characterisation of lipidic formulations and prediction of in vivo exposure

  2017cites this paper
• In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey.

  2017cites this paper
• Benito-Gallo, Paloma and Marlow, Maria and Zann, Vanessa and Scholes, Peter and Gershkovich, Pavel (2016) Linking in vitro lipolysis and microsomal metabolism for the quantitative prediction of oral bioavailability of BCS II drugs administered in lipidic

  2017cites this paper
• Investigating the Impact of Drug Crystallinity in Amorphous Tacrolimus Capsules on Pharmacokinetics and Bioequivalence Using Discriminatory In Vitro Dissolution Testing and Physiologically Based Pharmacokinetic Modeling and Simulation.

  2017cites this paper
• Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.

  2016cites this paper
• Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1

  2016cites this paper
• Prediction of oral drug bioavailability : from animal-based extrapolation towards the application of physiologically-based pharmacokinetic modelling and simulation

  2016cites this paper
• Risk Assessment of Drug–Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients

  2016cites this paper
• An update on the role of intestinal cytochrome P450 enzymes in drug disposition

  2016cites this paper
• Variation in Methodologies – Isolation of Intestinal Microsomes

  2016cites this paper
• Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin

  2016cites this paper
• Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models

  2016influential citation
• Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination

  2016cites this paper
• Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example.

  2016cites this paper
• Methodology of oral formulation selection in the pharmaceutical industry.

  2016cites this paper
• The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model

  2016cites this paper
• Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach

  2016cites this paper
• Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective

  2016cites this paper
• Presystemic and First‐Pass Metabolism

  2016cites this paper
• Linking in Vitro Lipolysis and Microsomal Metabolism for the Quantitative Prediction of Oral Bioavailability of BCS II Drugs Administered in Lipidic Formulations.

  2016cites this paper
• Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model

  2015influential citation
• Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption

  2015cites this paper
• A New Physiologically Based Pharmacokinetic Model for the Prediction of Gastrointestinal Drug Absorption: Translocation Model

  2015cites this paper
• Dealing with the complex drug-drug interactions: towards mechanistic models.

  2015cites this paper
• Development and applications of physiologically-based pharmacokinetic models for population data analyses

  2015cites this paper
• Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model.

  2015cites this paper
• A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows

  2015cites this paper
• The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development

  2015cites this paper
• Drug-induced cholestasis detection in cryopreserved rat hepatocytes in sandwich culture.

  2015cites this paper
• Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes.

  2015cites this paper
• Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction

  2015cites this paper
• Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate

  2014cites this paper